



# JAGSONPAL PHARMACEUTICALS LIMITED

Regd. office : T-210 J, Shahpur Jat, New Delhi-110 049 (INDIA)

Fax : 0091-11-26498341,26494708, Phone: 0091-11-26494519-24

E-mail: admin@jagsonpal.com

Unaudited Financial Results for the Quarter ended 30.06.2010

Particulars		(Rs. in lacs)		
		Quarter ended 30.06.2010 Unaudited	Quarter ended 30.06.2009 Unaudited	12 Months ended 31.03.2010 Audited
1(a)	Net sales/Income from Operations	4117.04	3330.12	13959.34
1(b)	Other Operating Income			
	<b>Total</b>	<b>4117.04</b>	<b>3330.12</b>	<b>13959.34</b>
2	Expenditure			
a.	(Inc./Dec. in Stock in trade and work in progress	148.55	-120.89	-1042.09
b.	Consumption of Raw Materials	1952.83	1575.08	7219.40
c.	Purchase of traded goods	133.31	423.17	1372.92
d.	Employees Cost	684.81	516.24	2378.78
e.	Depreciation	57.02	49.78	208.50
f.	Other Expenditure	706.17	599.39	2458.50
g.	<b>Total</b>	<b>3682.69</b>	<b>3042.97</b>	<b>12596.01</b>
3	Profit from Operations before Other Income, Interest and Exceptional Items (1-2)	434.35	287.15	1363.33
4	Other Income	0.00	0.00	36.30
5	Profit before Int. & Exceptional Items (3+4)	434.35	287.15	1399.63
6	Interest	75.72	97.00	349.62
7	Profit After Interest but before Exceptional items (5 - 6)	358.63	190.15	1050.01
8	Exceptional Items			
9	Profit(+)/Loss(-) from Ordinary Activities before tax (7 +8)	358.63	190.15	1050.01
10	Tax expense	35.00	40.00	125.81
11	Net Profit(+)/Loss(-) from Ordinary Activities after tax (9-10)	323.63	150.15	924.20
12	Extraordinary items (net of tax expense)			
13	Net Profit (+)/ Loss (-) for the period (11-12)	323.63	150.15	924.20
14	Paid up Eq. Sh. Cap.(Face value Rs. 5)	1309.90	1309.90	1309.90
15	Reserves excluding Revaluation reserves as per Balance sheet of pr. accounting yr. Earnings Per Share (EPS)			<b>6049.30</b>
a.	Basic & diluted EPS before extraordinary items for the period.	1.24	0.57	3.53
b.	Basic & diluted EPS after extraordinary items for the period.	1.24	0.57	3.53
17	Public shareholding :			
	- Number of shares	8962360	8962360	8962360
	- Percentage of Shareholding	34.21%	34.21%	34.21%
18	Promoter and promoter group shareholding			
a.	Pledged / Encumbered			
	- Number of shares	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-
b.	Non - encumbered			
	- Number of shares	17235640	17235640	17235640
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%	100%	100%
	- Percentage of shares (as a % of the total share capital of the Company)	65.79%	65.79%	65.79%

#### Notes

- The Financial Results for the Quarter ended 30.6.2010 have been reviewed by the Auditors as well as Audit Committee. The Board of Directors has taken on record the financial Results at its meeting held on 13-8-2010
- No complaints were pending at the beginning/end of the quarter ended 30.6.2010. However 11 requests for change of address/dividend revaluation/Annual Reports etc. were received & promptly responded to during the quarter.
- The Company is operating only in the Pharmaceuticals segment and hence compliance has been made under AS-17.
- The net effect of the deferred taxation for the Quarter as per AS-22 has been taken.
- The Board has recommended a Dividend of Rs 0.50 per equity Share on 2,61,98,000 equity shares of Rs. 5/- each for the year 2009-10.

By Order of the Board  
For Jagsonpal Pharmaceuticals Limited

Rajpal Singh Kochhar  
Managing Director



Place : New Delhi  
Date : 13.08.2010

Factory : 20 K.M. Mathura Road, Post Office Amar Nagar, Faridabad-121003 (India) Phone:0091-95129-2275952, 2275953